VIPIDIA (alogliptin) and VIPDOMET (alogliptin/metformin), antidiabetics

No clinical benefit demonstrated in the management of patients with type 2 diabetes

• VIPIDIA has Marketing Authorisation in the treatment of type 2 diabetes in combination with other blood glucose-lowering medicines, including insulin, when these, combined with diet and exercise, do not provide adequate glycaemic control.
• Its efficacy has been demonstrated in patients inadequately controlled in dual therapy with metformin or a sulfonylurea and in triple therapy with insulin and metformin.
• VIPDOMET has Marketing Authorisation in the treatment of type 2 diabetes:

- in adult patients inadequately controlled by the maximum tolerated dose of metformin in monotherapy, or in those already receiving an alogliptin-metformin combination.

- in combination with pioglitazone in adult patients inadequately controlled by the maximum tolerated dose of metformin and pioglitazone.

- in combination with insulin in patients for whom a stable dose of insulin and metformin alone is not sufficient to provide adequate glycaemic control.

• The fixed-dose combination of alogliptin/metformin has not shown any clinical added value compared with the free combination of alogliptin and metformin.